Kiniksa had a successful first half of 2020, with positive results from studies of rilonacept and vixarelimab, as well as mavrilimumab data published in The Lancet Rheumatology. The company is planning to submit an sBLA to the FDA for rilonacept in recurrent pericarditis this year. Evaluations of mavrilimumab and vixarelimab are progressing, and data is expected in the fourth quarter from the mavrilimumab GCA trial and the KPL-404 program. Recent capital raises and financial discipline are expected to extend the company's cash runway into 2023.
Statistically significant results from the pivotal Phase 3 study of rilonacept in recurrent pericarditis.
Positive results from the Phase 2a study of vixarelimab in prurigo nodularis.
COVID-19 mavrilimumab data published in The Lancet Rheumatology.
sBLA submission to the FDA for rilonacept in recurrent pericarditis planned for this year.
Kiniksa expects a catalyst-filled second half of the year with multiple data readouts and a planned sBLA submission.
Analyze how earnings announcements historically affect stock price performance